Pharmaceuticals

Asclepius Meditec's Hydrogen Oxygen Generator with Nebulizer is Expected to Alleviate the Oxygen Shortage Crisis during COVID-19 Pandemic

SHANGHAI, May 1, 2021 /PRNewswire/ -- In June, 2020, an academic paper on patients with COVID-19 inhaling hydrogen oxygen mixed gas produced by Asclepius Meditec's Hydrogen Oxygen Generator with Nebulizer was published in the Journal of Thoracic Disease. The multicenter, and open-label clinical t...

2021-05-01 17:17 4553

BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark Application Filed for CoviDTH(R) Diagnostic

Commercial trademark application FILED for CoviDTH® diagnostic cancer vaccine platform patent coverageexpanded to NOW include over 12 tumor types VANCOUVER, B.C., April 29, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "the Company"), the world ...

2021-04-29 20:56 2866

Hilco Industrial Acquires All Machinery & Equipment from Legacy Pharmaceutical Switzerland

BASEL, Switzerland, April 29, 2021 /PRNewswire/ -- Hilco Industrial Acquisitions, anAmsterdam-based Industrial Asset Disposition and Acquisition Company, acquired all Machinery & Equipment from theSwiss-based CMO Legacy Pharmaceuticals. After several years of expansion, the Swiss company was forc...

2021-04-29 13:04 1673

Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib)

SUZHOU, China, April 29, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966HK) announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer to evaluate the efficacy and safety of KN046 in combination with Inlyta® (axitinib) for the first-line treatment ...

2021-04-29 08:00 4542

Innovent Announces First Patient Dosed in the Phase 2 Clinical Trial of IBI302, a First-in-class Ophthalmic Anti-VEGF and Anti-Complement Bispecific Fusion Protein for Neovascular Age-Related Macular Degeneration

SAN FRANCISCO and SUZHOU, China, April 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...

2021-04-29 08:00 4517

AnchorDx Jointly Publishes Clinical Research Paper: "Accurate Diagnosis of Pulmonary Nodules Using a Non-invasive DNA Methylation Test"

GUANGZHOU, China, April 28, 2021 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer screening and early detection solutions, together with renowned thoracic experts from 14 top-tier hospitals inChina, jointly published a clinical research paper entitled "Accurate Diagnosis of Pulmonary...

2021-04-28 21:00 1560

Novaliq Announces More than 50% Patients Enrolled in CyclASol® Phase 3 Dry Eye Disease Trial ESSENCE-2

- Topline results expected in 2nd half 2021; 475 out of a 834 target patients randomized in ESSENCE-2 - Enrollment for 12-month safety extension trial (ESSENCE-2 OLE) completed - Phase 2B/3 Trial ESSENCE-1 Published in Cornea: The Journal of Cornea and External Disease HEIDELBERG, Germany and C...

2021-04-28 20:00 1449

CROs dMed and Clinipace Merge to Accelerate Customer Success

SHANGHAI and MORRISVILLE, N.C., April 28, 2021 /PRNewswire/ -- dMed Global, a full-service Clinical Contract Research Organization (CRO) based inShanghai, China, and Clinipace Incorporated, a full-service Clinical CRO with headquarters inNorth Carolina, USA, announced today that the two companies...

2021-04-28 20:00 2816

Hovid Berhad Partners with Esker to Automate its Accounts Payable Process

SINGAPORE, April 27, 2021 /PRNewswire/ -- Esker , a globalcloud platform  and leader inAI-driven process automation solutions  for finance and customer se...

2021-04-27 09:35 1915

DiscGenics Completes Patient Enrollment in Japanese Clinical Study of Cell Therapy for Disc Degeneration as US Study Achieves One-Year Follow-up Milestone

SALT LAKE CITY and TOKYO, April 27, 2021 /PRNewswire/ -- DiscGenics, Inc., a clinical stage biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that it has c...

2021-04-27 09:23 2219

Himalaya Therapeutics Announces Appointment of Brian Zhang as Chief Executive Officer

SAN DIEGO, April 26, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, which are based ...

2021-04-26 22:08 2028

CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R) (Pralsetinib) with Priority Review Designation for the Treatment of Advanced or Metastatic RET-Altered Thyroid Cancer Patients

SUZHOU, China, April 26, 2021 /PRNewswire/ -- CStone Pharmaceuticals (CStone, HKEX: 2616), a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today announces that the National Medical Products Administration ...

2021-04-26 21:14 3380

INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800

Given universal eligibility and broad availability of COVID-19 vaccines in the U.S., DoD JPEO-CBRND has notified INOVIO that it will discontinue funding for the Phase 3 INO-4800 trial INOVIO adjusts INO-4800 clinical development strategy to focus on global unmet COVID-19 vaccine needs PLYMOUTH ...

2021-04-23 20:00 4468

Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova

STOCKHOLM, April 23, 2021 /PRNewswire/ -- Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health mark...

2021-04-23 15:22 1720

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review

SHANGHAI, April 23, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...

2021-04-23 15:00 1920

The NDA of the Novel Anti-PD-1 mAb Serplulimab of Henlius Accepted by NMPA and Proposed to be Granted Priority Review

SHANGHAI, April 22, 2021 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the New Drug Application (NDA) of serplulimab injection (HLX10), a novel anti-PD-1 monoclonal antibody (mAb), for the treatment of unresectable or metastatic microsatellite instability-high (MSI-H) s...

2021-04-22 21:47 3134

RDIF and Minapharm agree to produce over 40 million doses of the Sputnik V vaccine in Egypt

MOSCOW, CAIRO and BERLIN, April 22, 2021 /PRNewswire/ -- The Russian Direct Investment Fund (RDIF,Russia's sovereign wealth fund), Egypt's Minapharm, the regional leader in recombinant DNA technology, and itsBerlin-based subsidiary, ProBioGen AG, announce the agreement to produce over 40 million ...

2021-04-22 16:00 2461

Seegene to supply COVID-19 diagnostic tests worth 16 mil. GBP to Scotland, triple the sales volume seen last year

* Second public procurement agreement after Italy's procurement deal worth EUR 89.3 million SEOUL, South Korea, April 22, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), a leading biotechnology firm said it began supplying its COVID-19 diagnostic tests worth16,209,150 GBP to Scotland under a pub...

2021-04-22 09:37 2930

endpoint Launches ConnectionPOINT™ - A partnership program designed to power accelerated outcomes and move medicine through next-generation eClinical technology interfacing

SAN FRANCISCO, April 21, 2021 /PRNewswire/ -- endpoint Clinical, the leading global interactive response technology (IRT®) company, announced today the launch of their partnership program,ConnectionPOINT™, the first of its kind in the eClinical technology space.  The program's vision is for a g...

2021-04-21 21:00 2920

Cobots Lead the Future of the Global Industrial Robots Market, Finds Frost & Sullivan

Asia-Pacific to remain the epicenter of growth opportunities for robot manufacturers, with market revenues estimated to top$25.08 billion by 2024 SANTA CLARA, Calif., April 21, 2021 /PRNewswire/ -- Frost & Sullivan's recent analysis finds that theglobal industrial robotics market will reach reven...

2021-04-21 20:48 2286
1 ... 126127128129130131132 ... 184